Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Devonian Health Group's operating assets for the quarter that ended in Jan. 2026 was $6.01 Mil. Devonian Health Group's operating liabilities for the quarter that ended in Jan. 2026 was $1.10 Mil. Devonian Health Group's Total Assets for the quarter that ended in Oct. 2025 was $11.13 Mil. Therefore, Devonian Health Group's scaled net operating assets (SNOA) for the quarter that ended in Jan. 2026 was 0.44.
Devonian Health Group Scaled Net Operating Assets Related Terms
Devonian Health Group Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Devonian Health Group's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Devonian Health Group Scaled Net Operating Assets Chart
DVHGF vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison
For the Biotechnology subindustry, Devonian Health Group's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Devonian Health Group Scaled Net Operating Assets vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Devonian Health Group's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Devonian Health Group's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.44 mean?
Devonian Health Group (DVHGF) has a Scaled Net Operating Assets of 0.44 as of Jan. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Devonian Health Group and its competitors.
Is Devonian Health Group's Scaled Net Operating Assets too high?
Devonian Health Group's current Scaled Net Operating Assets is 0.44. Overall, Devonian Health Group has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Devonian Health Group's Scaled Net Operating Assets compare to VRTX and REGN?
Devonian Health Group's Scaled Net Operating Assets of 0.44 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Devonian Health Group and its competitors. Devonian Health Group's current Scaled Net Operating Assets is 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Devonian Health Group stock overvalued right now?
Based on GuruFocus' analysis, Devonian Health Group (DVHGF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.02, compared to a current price of $7.00 — trading 131.8% above its estimated fair value. The current Scaled Net Operating Assets is 0.44. Devonian Health Group's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Devonian Health Group (DVHGF), the current Scaled Net Operating Assets is 0.44 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Devonian Health Group (DVHGF) Overvalued in 2026?
Based on GuruFocus' analysis, Devonian Health Group stock appears to be overvalued.
The current stock price of $7.00 is trading 131.8% above its estimated GF Value™ of $3.02.
GuruFocus considers Devonian Health Group to be Significantly Overvalued.
Key valuation signals for DVHGF:
Scaled Net Operating Assets: 0.44
GF Value™: $3.02 vs. price of $7.00 (131.8% above fair value)
No single metric tells the full story. See the DVHGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.
49GF Score
Get the complete analysis for DVHGF
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVHGF has been successfully added to your 
